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227 Prevalence of bile acids in saliva of children with cystic ﬁbrosis
and relation with disease parameters and medication use
M. Proesmans1, A. Pauwels2, S. Matthe´3, K. Blondeau2, D. Sifrim4, K. De
Boeck1. 1University Hospital Leuven, Dept of Paediatric Pulmonology, Leuven,
Belgium; 2University Hospital Leuven, Center for Gastroenterological Research,
Leuven, Belgium; 3University Hospital Leuven, Dept of Pediatrics, Leuven,
Belgium; 4Barts and The London School of Medicine and Dentistry, Upper GI
Physiology, London, United Kingdom
Increased gastrooesophageal reﬂux has a high prevalence in CF children and seems
to be a primary phenomenon. It is well known that GOR can cause or aggravate lung
disease. Tests to quantify acid and non-acid reﬂux are cumbersome and the relation
with airway disease is difﬁcult to establish. A variety of bile acids can be detected
in the oesophageal reﬂuxate of patients with GOR disease. It has been shown that
bile acids and pepsine are detecable in BAL and saliva of a high proportion of
CF patients. The relevance of this ﬁnding is as yet not clear.
Aim: Repeated measurement of bile acids in saliva in a cohort of 120 children with
CF and correlation with parameters of lung disease and medication use.
Result: Saliva samples were obtained in 63 children (mean age 10.5 year SD 4.1)
in 2007 and 90 in 2009 (mean age 10.2 SD 4.6). Bile acids were detected in 23/63
in 2007 (median and IQ range 4.85 mmol/l 3.03−6) and in 28/90 patients in 2009
(median and IQ range 1.05mmol/l 0.74−2.1). 52 patients were sampled at both
times while for 31 samples results were concordant. Correlation of salivary bile
acids and age, genotype, LF, LF decline, colonization status, IgG, antibiotic need
will be presented. Use of ursodeoxycholic acids, proton pump inhibitors, cisapride,
macrolides is studied as well.
Conclusion: Prevalence of measurable bile acids in saliva in CF children is around
30%. Correlation with disease parameters will be presented.
228 The importance of looking at small airways function in patients
with cystic ﬁbrosis (CF) not responding to routine therapy
K. Hurt1,2, D. Bilton1,2, K. Gyi1,2, M. Hodson1,2. 1Royal Brompton Hospital,
London, United Kingdom; 2Imperial College, London, United Kingdom
Introduction: There are a group of patients with CF that have a predominant picture
of small airways abnormality. We report 4 cases of patients who have evidence of
small airways dysfunction that responded to high dose steroids after failing to
respond to initial routine treatments.
Methods: Data was recorded from hospital notes and the Electronic Patient Record.
Results: Patient A: 23 year old female who was hypoxaemic during an exacer-
bation of CF. She failed to respond to standard treatments but made an excellent
improvement with resolution of the hypoxaemia after methylprednisolone (1g od
for 3 days).
Patient B: 19 year old male who had a year of lung function decline. He failed to
respond to usual treatments. After treatment with methylprednisolone (1 g od for
3 days) his lung function improved signiﬁcantly.
Patient C (27 year old female) and Patient D (35 year old female) both deteriorated
with a signiﬁcant reduction in small airways function. They were treated with
standard therapies plus high dose I.V. hydrocortisone and prednisolone respectively.
They made excellent recoveries.
Summary of lung function pre and post treatment
Patient A Patient B Patient C Patient D
Pre Post Pre Post Pre Post Pre Post
FEV1 (L) 1.62 1.69 1.80 2.20 1.45 1.77 2.12 2.92
MEF75 (L/S) 1.61 2.11 1.79 2.89 1.21 1.67 2.77 4.18
MEF25 (L/S) 0.18 0.30 0.16 0.29 0.13 0.26 0.32 0.68
RV%TLC (%) − − 170 150 192 161 137 106
Conclusion: This case series demonstrates that patients with small airways abnor-
malities may beneﬁt from high dose steroids. Current tests of small airways function
are inadequate but experimental tests such as impulse oscillometry may be useful
for identiﬁcation of patients with small airway dysfunction.
229 3D reconstructions in CF: possibilities and challenges
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W. De Backer1. 1University Hospital Antwerp, Edegem, Belgium; 2FluidDA,
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Small airways (SA) play an important role in (early) CF and therefore therapy should
be aimed to target the SA. Effects of CF on SA are evaluated using CT scoring
systems (e.g. Brody) that correlate with lung function (LF). Since these scoring
systems are rather complicated we have developed a method to directly evaluate
(distal) airways (DA) from 3D CT reconstruction and showed good correlation with
LF in adults (J Biomech 2008; 41(1): 106−13). The purpose of this study was to
apply these techniques in pediatric CF patients to evaluate its added value in early
disease progression.
A retrospective, observational analysis was performed for 5 CF patients with limited
LF decline over a period of 2 years. From CT scans at the beginning and end of this
period, lobar volumes and growths were calculated and 3D models of the airways
were generated. These were compared with LF changes, clinical symptoms and
treatment data.
All 5 patients (13 y [9−21] at inclusion) showed a FEV1 decline of less than 1%pred
per year with no major increase in clinical symptoms. For 4 patients, as expected,
the lobar volumes (%) at TLC and lobar growths (%) did not change. However, the
3D models of the airways showed initial, local DA inﬂammation and formation of
bronchiectasies that were undetected by LF. The remaining patient showed drastic
changes in lobar volumes and airway structures with unchanged LF.
It can be concluded that 3D CT models can detect local airway changes which
remain undetected with LF. This can signiﬁcantly beneﬁt early detection of CF
progression. Future challenges are aimed at correlating changes observed in 3D CT
models with disease progression and treatment response.
230 The use of acetazolomide in adults with cystic ﬁbrosis and
hypercapnia
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1Leeds Regional Adult Cystic Fibrosis Unit, Leeds, United Kingdom
Introduction: The major cause of mortality in people with Cystic Fibrosis (CF)
is respiratory failure. Non-invasive ventilation (NIV) may stabilise this but may
be difﬁcult to tolerate, have potential risks or not fully resolve respiratory failure
in some patients. Acetazolomide is a carbonic anhydrase inhibitor which increases
renal excretion of bicarbonate inducing mild metabolic acidosis and increasing
ventilation with a favourable shift in the oxygen dissociation curve. It has been
used to treat respiratory failure in COPD.
Methods: Seven adults with CF, who demonstrated type II respiratory failure and
who either did not use NIV (n = 5) or whose hypercapnia was not adequately
controlled with NIV (n = 2), commenced Acetazolomide 250mg twice a day. Those
on NIV and/or oxygen therapy continued this. Blood gases were analysed pre and
post ﬁve days of Acetazolomide.
Results: Results are presented as median and range (Table 1). Signiﬁcant reductions
in HCO3−, pCO2 and base excess were seen along with a signiﬁcant increase in
pO2. One patient reported side effects of headache and minor dizziness, symptoms
she had prior to using Acetazolomide but which were increased during use.
Conclusion: Acetazolomide is safe to use in adults with CF although there may
be minor side effects. It is unclear whether the correction of blood gases by use of
Acetazolomide will alter mortality or morbidity.
Table 1
Measure Pre Acetazolomide Post Acetazolomide Absolute change P value
pCO2 7.82 (7.32–9.16) 6.78 (5.34–7.65) 1.51 (0.75–2.33) 0.0049
pO2 7.6 (6.3−9.7) 8.5 (7.9–10.5) 1.3 (0.1−2.0) 0.0253
pH 7.44 (7.38–7.51) 7.41 (7.36–7.46) 0.03 (0.045–0.085) 0.1797
HCO3− 40.8 (36.8–44.8) 31.1 (28.4–35.3) 9.5 (8.1–12.3) 0.0022
BE 16 (12−21) 6 (5−11) 10 (7−13) 0.0022
